Company profile: TME Pharma
1.1 - Company Overview
Company description
- Provider of biostable aptamer therapeutics based on mirror image nucleic acids, including NOX-A12 to enhance anti-cancer treatments in glioblastoma and pancreatic cancer and NOX-E36 to improve tumor immune response. Operates GLORIA, OPERA & OPTIMUS trials, and pursues collaborations, including a strategic alliance with Pfizer.
Products and services
- NOX-A12: A biostable RNA aptamer targeting CXCL12 that enhances anti-cancer treatment effectiveness in glioblastoma and pancreatic cancer without significant side effects
- OPERA & OPTIMUS trials: Combination-therapy clinical trials in collaboration with MSD/Merck evaluating NOX-A12 with pembrolizumab and chemotherapy in pancreatic cancer patients
- GLORIA Phase 1/2 clinical trial: Phase 1/2 clinical trial assessing NOX-A12 combined with radiotherapy and other treatments in glioblastoma patients resistant to standard chemotherapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TME Pharma
Oncternal Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology treatments, developing a pipeline including ONCT-808, a ROR1-targeting autologous CAR T in Phase 1/2 for relapsed or refractory aggressive B-cell lymphoma; ONCT-534, a dual-action androgen receptor inhibitor for metastatic castration-resistant prostate cancer; and zilovertamab, a ROR1-targeting monoclonal antibody evaluated with other treatments for various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncternal Therapeutics company profile →
Nerio Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology for the life sciences sector; founded in 2019 and based in La Jolla, CA, USA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nerio Therapeutics company profile →
Quantum Surgical
HQ: France
Website
- Description: Provider of robotic-assisted interventional oncology solutions for minimally invasive liver cancer treatment, including Epione for planning, targeting, delivery and confirmation of tumor ablation; CT/MRI fusion-based multimodal planning; real-time respiratory monitoring; post-ablation margin verification; and robotic guidance with navigation and haptics (6 DOF) for precise targeting and safe needle release.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantum Surgical company profile →
Allegro Diagnostics
HQ: United States
Website
- Description: Provider of genomic tests in development to support the diagnosis and management of lung cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allegro Diagnostics company profile →
Wugen
HQ: United States
Website
- Description: Provider of off-the-shelf allogeneic cellular therapies for solid tumors and hematologic malignancies, including WU-NK-101, a memory NK cell therapy, and WU-CART-007, a CD7-targeting CAR-T for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; plus Memory NK and CAR-T platforms enabling feeder-free cryopreserved NK cells and donor-derived CAR-T cells engineered to reduce fratricide and Graft vs. Host Disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wugen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TME Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TME Pharma
2.2 - Growth funds investing in similar companies to TME Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TME Pharma
4.2 - Public trading comparable groups for TME Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →